ParaNano adds Rod Whitson as chairman and Lora Spencer to board leadership

ParaNano on June 16, 2026 named Rod Whitson chairman of the board and Lora Spencer, Esq. chair of its Executive Compensation Committee as the wound care company pushes commercialization of its Bio-Z technology. The appointments bring operating, legal and healthcare industry experience to a board preparing for the company’s next growth phase. Why it matters: - ParaNano is trying to move its wound care technology closer to commercialization. - The board adds leadership experience in growth-stage operations, healthcare law, governance and life sciences. - Stronger board oversight can matter as a medical technology company prepares for scale, partnerships and regulatory complexity. What happened: - ParaNano appointed Rod Whitson as chairman of the board. - ParaNano appointed Lora Spencer, Esq. as chair of the Executive Compensation Committee. - The company announced the moves on June 16, 2026. - The appointments are part of a broader effort to strengthen leadership as ParaNano advances its wound care technology. The details: - Whitson is an Entrepreneurial Operating System® Implementer and executive leader with experience scaling entrepreneurial and growth-stage companies. - Whitson has helped lead six entrepreneurial businesses and served as CEO and president of three financial services firms. - Whitson previously served as president of Townsend Agency, a San Diego-based technology marketing firm. - At Townsend Agency, Whitson led strategic engagements for biotechnology and life sciences companies including Merck Bioscience, Dow Pharma, Accelrys, Gen-Probe, Diversa, Agilent and Applied Molecular Evolution. - Whitson also worked with technology companies including Toshiba, QUALCOMM, Intel, BAE Systems and ARM. - Whitson is an angel investor with multiple exits and serves on several boards and advisory boards. - Spencer brings experience across medical devices, pharmaceuticals, biotechnology and healthcare technology. - Spencer is chief legal counsel for Mechanical Circulatory Support at Medtronic and senior litigation and investigations counsel. - Spencer defends Medtronic in global litigation matters and advises senior leadership on enterprise risk, litigation, governance and strategic business matters. - Spencer serves on Medtronic’s AI Legal Practice Group and AI Litigation Task Force. - At Medtronic, Spencer advises on AI-driven healthcare technologies, products liability and litigation trends. - Before Medtronic, Spencer handled complex litigation and regulatory matters for medical device and pharmaceutical companies at a global law firm. - Spencer was a Presidential Management Fellow at the National Institutes of Health. - Spencer later joined the National Cancer Institute, where she oversaw pre-clinical trial portfolios and advised on drug development, regulatory and policy matters. - Spencer also held commercial and leadership roles at Pfizer and Sanofi. - Spencer is a Johnson & Johnson Board Fellows alum and completed executive education at Harvard Business School focused on corporate directorship. - CEO and co-founder Chelsea Luxen said Spencer’s legal governance and life sciences experience and Whitson’s operational focus are important for upcoming commercial milestones. - ParaNano’s Bio-Z™ technology platform is designed to provide a visual indication of pathogenic activity through a color-changing nanofiber system integrated into wound care applications. Between the lines: - ParaNano is signaling that commercialization will require both operational discipline and governance sophistication. - The board choices also suggest the company wants deeper credibility with healthcare, legal and growth-oriented stakeholders. - The emphasis on AI, litigation and enterprise risk reflects the regulatory and liability pressures facing modern healthcare technology companies. What’s next: - ParaNano is preparing for its next phase of growth. - The company is advancing commercialization of its wound care technology. - The new board leadership is likely to play a role in future strategic, governance and compensation decisions as ParaNano scales. The bottom line: - ParaNano is building a board with operating and legal firepower as it moves its Bio-Z wound care platform toward market expansion.